TruScreen FY2025 Preliminary Results
Key market China, accounted for more than 85% of global sales exceeded budget and is poised for further expansion in 6 key provinces
Memorandum of Understanding signed with Hangzhou Dalton Bioscience (DaltonBio) in February 2025 to form a strategic alliance for expanding product portfolio and distribution channels
TruScreen re-enters India with appointment of Renovate Biologicals Pvt Ltd in April 2025
5-year program to screen 260,000 women for cervical cancer in Ho Chi Minh City, Vietnam launched April, 2025
Indonesia product registration completed and distributor appointed, with commercial activity commenced in May 2025
TruScreen clinical trial results confirm suitability for large scale screening in emerging markets
TruScreen continues to be validated by independent studies and the World Health Organization